Article

The Importance of Clinical Trials in Multiple Myeloma

As patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

The list of available treatment options for multiple myeloma has grown in the past decade, However, as patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

In an interview with OncLive®, CURE®’s sister publication, Mailankody explained how investigational drugs can play a role in the treatment of patients with myeloma as they advance past the initial lines of treatment.

Transcription:

I think with all these different treatment options, particularly in the relapsed/refractory setting, referring patients when appropriate to clinical trials of these novel treatments — for instance, the CAR-T cells and bispecific antibodies and others that are coming along that are not currently available as standard treatments but might provide significant clinical benefit for patients in the context of clinical trials — would be something else I think people should keep in mind as they see patients through their treatment course.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.